Methoxetamine: From drug of abuse to rapid-acting antidepressant

被引：28
|
作者：
Coppola, M. [1 ]
Mondola, R. [2 ]
机构：
[1] ASL CN2, Dept Addict, I-12051 Alba, CN, Italy
[2] ASL CN1, Dept Mental Hlth, I-12037 Saluzzo, CN, Italy
来源：
MEDICAL HYPOTHESES | 2012年 / 79卷 / 04期
关键词：
MAJOR DEPRESSIVE DISORDER; D-ASPARTATE ANTAGONIST; RESISTANT BIPOLAR DEPRESSION; STAR-ASTERISK-D; ELECTROCONVULSIVE-THERAPY; ALCOHOL DEPENDENCE; SIGMA-RECEPTORS; CHRM2; GENE; RAT-BRAIN; KETAMINE;
D O I：
10.1016/j.mehy.2012.07.002
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Methoxetamine is a dissociative anaesthetic showing pharmacodynamic similarities with its analogue ketamine, a medication with demonstrated rapid-acting antidepressant effects. Like ketamine and other arylcyclohexylamine compounds, methoxetamine is thought to be both a noncompetitive NMDA receptor antagonist and a dopamine reuptake inhibitor. Furthermore, it acts as an agonist at dopamine D2, serotonin 5HT2, muscarinic cholinergic, sigma-1, opioid mu and k receptors. The hypothesis is that methoxetamine can produce rapid antidepressant effects in patients with resistant and non-resistant unipolar and bipolar depression. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码：504 / 507
页数：4
相关论文
共 50 条
  • [21] Synaptic mechanisms underlying the rapid-acting antidepressant actions of ketamine
    Zobel, Allison
    Pope, Brock
    Rehman, Zarin
    Herring, Laura
    Wauson, Eric
    Graves, Lee
    Duric, Vanja
    Yuan, LiLian
    FASEB JOURNAL, 2018, 32 (01):
  • [22] Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant
    Ballard, Elizabeth D.
    Luckenbaugh, David A.
    Richards, Erica M.
    Walls, Tessa L.
    Brutsche, Nancy E.
    Ameli, Rezvan
    Niciu, Mark J.
    Vande Voort, Jennifer L.
    Zarate, Carlos A., Jr.
    JOURNAL OF PSYCHIATRIC RESEARCH, 2015, 68 : 68 - 73
  • [23] Biologically plausible models of neural dynamics for rapid-acting antidepressant interventions
    Gilbert, Jessica R.
    Zarate, Carlos A., Jr.
    NEUROPSYCHOPHARMACOLOGY, 2021, 46 (01) : 231 - 232
  • [24] Sex Differences in the Temporal Neuromolecular and Synaptogenic Effects of the Rapid-acting Antidepressant Drug Ketamine in the Mouse Brain
    Thelen, Connor
    Flaherty, Emily
    Saurine, Joseph
    Sens, Jonathon
    Mohamed, Sara
    Pitychoutis, Pothitos M.
    NEUROSCIENCE, 2019, 398 : 182 - 192
  • [25] Arketamine, a new rapid-acting antidepressant: A historical review and future directions
    Zhang, Ji-chun
    Yao, Wei
    Hashimoto, Kenji
    NEUROPHARMACOLOGY, 2022, 218
  • [26] Neurobiological mechanisms underlying rapid-acting antidepressant actions: is BDNF the key?
    Monteggia, L.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S528 - S528
  • [27] Biologically plausible models of neural dynamics for rapid-acting antidepressant interventions
    Jessica R. Gilbert
    Carlos A. Zarate
    Neuropsychopharmacology, 2021, 46 : 231 - 232
  • [28] Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
    Kadriu, Bashkim
    Musazzi, Laura
    Henter, Ioline D.
    Graves, Morgan
    Popoli, Maurizio
    Zarate, Carlos A., Jr.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2019, 22 (02): : 119 - 135
  • [29] Rapid-Acting Antidepressants
    Witkin, Jeffrey M.
    Knutson, Daniel E.
    Rodriguez, Gabriel J.
    Shi, Samuel
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (22) : 2556 - 2563
  • [30] Sedative drugs activate signaling pathways implicated in rapid-acting antidepressant effects
    Kohtala, S.
    Theilmann, W.
    Matsui, N.
    Klein, A.
    Rantamaki, T.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S640 - S640
12345